Iradimed (NASDAQ:IRMD) Updates FY 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.710-1.810 for the period, compared to the consensus estimate of 1.750. The company issued revenue guidance of $78.0 million-$82.0 million, compared to the consensus revenue estimate of $80.7 million. Iradimed also updated its Q1 2025 guidance to 0.390-0.430 EPS.

Analysts Set New Price Targets

Several research firms have recently weighed in on IRMD. StockNews.com cut Iradimed from a "strong-buy" rating to a "buy" rating in a report on Thursday. Roth Mkm reissued a "buy" rating and issued a $72.00 price objective (up previously from $60.00) on shares of Iradimed in a research report on Friday.

Iradimed Stock Down 0.3 %

Shares of NASDAQ IRMD traded down $0.17 during mid-day trading on Monday, reaching $55.23. 51,661 shares of the company were exchanged, compared to its average volume of 36,478. The stock has a market capitalization of $699.76 million, a P/E ratio of 37.83 and a beta of 0.82. The company's 50-day simple moving average is $57.20 and its 200-day simple moving average is $52.18. Iradimed has a twelve month low of $40.18 and a twelve month high of $63.29.

Iradimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.05). The firm had revenue of $19.39 million for the quarter, compared to the consensus estimate of $19.09 million. Iradimed had a return on equity of 23.99% and a net margin of 26.12%. As a group, equities research analysts expect that Iradimed will post 1.52 EPS for the current year.

Iradimed Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 5th. Shareholders of record on Monday, February 24th will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date of this dividend is Monday, February 24th. This is a positive change from Iradimed's previous quarterly dividend of $0.15. Iradimed's dividend payout ratio (DPR) is 41.10%.

Insider Activity

In related news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the sale, the chief financial officer now directly owns 4,383 shares of the company's stock, valued at approximately $237,470.94. The trade was a 36.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 37.10% of the company's stock.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.